• Prednisolone: Synthetic Glucocorticoid for Glucocorticoid Si

  2026-06-06

  Prednisolone is a high-purity synthetic glucocorticoid widely used for mechanistic studies of glucocorticoid receptor signaling and inflammation modulation. Its solubility profile, validated purity, and stability parameters make it a preferred reagent for immunology research and cellular response assays. APExBIO supplies Prednisolone (SKU B2012) for reproducible experimental outcomes.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 to Protect Against CI-A

  2026-06-05

  This study identifies the FXR-KLF11 axis as a key regulator in protecting against contrast-induced acute kidney injury (CI-AKI) by transcriptionally suppressing the JAK2/STAT3 pathway. The findings advance mechanistic understanding of CI-AKI and highlight the translational potential of FXR agonists as preventive therapeutics.

• Small-Molecule uPAR-uPA Inhibition Reduces Breast Cancer Met

  2026-06-05

  This study demonstrates that a synthesized small-molecule inhibitor, targeting the uPAR-uPA protein-protein interaction, can effectively reduce breast cancer metastasis in vivo. The findings highlight advances in inhibitor design and provide a framework for translational cancer research.

• Optimizing Western Blots for Translational Atherosclerosis R

  2026-06-04

  This article unites mechanistic insight on NHE1/Olfr2-driven atherosclerosis with advanced Western blotting strategies, focusing on how expert antibody management—specifically via the Western Secondary Antibody Dilution Buffer from APExBIO—elevates data reliability and translational value. We dissect how emerging inflammatory pathways demand precise protein detection, explore competitive solutions, and offer actionable guidance for researchers seeking both scientific rigor and operational efficiency.

• BOP Reagent (benzotriazol-1-yloxy-tris(dimethylamino)phospha

  2026-06-04

  This article addresses common laboratory challenges in peptide synthesis and cytotoxicity assay development, showing how BOP reagent (benzotriazol-1-yloxy-tris(dimethylamino)phosphanium hexafluorophosphate), SKU A7015, enables reproducible, high-yield peptide bond formation. Using scenario-driven Q&As, it provides evidence-based guidance integrating literature and practical workflow considerations, and links to APExBIO's product details for direct protocol adoption.

• ML385 NRF2 Inhibitor: Workflows & Innovations in Redox Resea

  2026-06-03

  ML385 stands out as a selective NRF2 inhibitor, enabling precise dissection of oxidative stress pathways and resistance mechanisms in cancer and neurodegeneration models. Recent breakthroughs, including the reversal of neuroprotection by ML385 in diabetic cognitive decline, position it as an essential tool for advanced redox and ferroptosis studies.

• Reactive Oxygen Species Assay Kit: DHE Probe in Action

  2026-06-03

  The APExBIO Reactive Oxygen Species Assay Kit (DHE) empowers researchers to precisely quantify intracellular superoxide, enabling robust oxidative stress and apoptosis studies. Unique protocol controls and workflow flexibility set this kit apart for both basic redox signaling research and advanced translational models.

• Abiraterone Acetate: CYP17 Inhibitor Workflows in Prostate C

  2026-06-02

  Abiraterone acetate, a potent CYP17 inhibitor, transforms prostate cancer research with its robust performance in 3D patient-derived spheroid models and conventional assays. Discover optimized experimental setups, troubleshooting strategies, and practical insights for maximizing its translational potential—directly informed by recent breakthroughs and advanced workflows.

• Merbromin: Strategic Mechanisms for Translational Success

  2026-06-02

  This thought-leadership article examines Merbromin (Mercury dibromofluorescein disodium salt) as a versatile probe and reagent in translational research. By blending mechanistic insights with strategic guidance, it addresses Merbromin’s unique fluorescence-based capabilities for protein–ligand analysis, its role in enzyme inhibition and antiviral screening, and its competitive standing in tissue marking and antimicrobial workflows. Backed by recent studies and comparative reviews, the discussion highlights experimental protocols, real-world limitations, and future directions for researchers seeking robust, evidence-based solutions.

• Phosbind Acrylamide: Elevating Protein Phosphorylation Analy

  2026-06-01

  Phos binding reagent (Phosbind) acrylamide empowers researchers to distinguish phosphorylated proteins with unmatched resolution—no antibodies required. This reagent streamlines SDS-PAGE phosphorylation detection, enabling mechanistic insights into complex signaling pathways such as the IKK/β-TrCP2-TFEB axis that governs autophagy and protein stability.

• D-Luciferin Sodium Salt: Gold-Standard Firefly Luciferase Su

  2026-06-01

  D-Luciferin sodium salt is a validated firefly luciferase substrate enabling precise ATP-dependent bioluminescence assays. Its high solubility and specificity support sensitive, non-invasive monitoring of cellular metabolism in oncology and immunotherapy research.

• IGF2BP1 Drives Macrophage Glycolysis and Fibrosis via THBS1

  2026-05-31

  This study uncovers a novel mechanism in pulmonary fibrosis: the m6A reader IGF2BP1 promotes macrophage glycolytic metabolism and fibrotic polarization by stabilizing THBS1 mRNA, ultimately enhancing TLR4 signaling. These insights clarify macrophage-driven fibrosis and highlight potential molecular targets for intervention.

• Targeted SPP1 Inhibition in Tumor Macrophages Reduces Tumor

  2026-05-30

  This study introduces a systematic small molecule screening approach to identify modulators of SPP1 in tumor-associated macrophages (TAM), culminating in a targeted nanoformulation that effectively decreases tumor size in preclinical models. The findings highlight a promising strategy for reprogramming the tumor immune microenvironment and advancing therapeutic options for solid tumors characterized by high immunosuppressive TAM burden.

• Recombinant Human Growth Hormone: IGFBP2-THBS1 Insights

  2026-05-29

  Explore new mechanistic frontiers in growth hormone translational research. This thought-leadership article integrates the latest findings on the IGFBP2-THBS1 axis with actionable strategic guidance for researchers, highlighting how APExBIO's recombinant human growth hormone (GH) empowers advanced mechanistic studies and next-generation assay design.

• Low-Affinity Blockade of N-Type Ca Channels by v-Agatoxin-IV

  2026-05-29

  This study reveals that the spider toxin v-agatoxin-IVA, while highly selective for P-type calcium channels at nanomolar concentrations, can also block N-type channels at higher (micromolar) concentrations, though with lower affinity. These findings refine the pharmacological understanding of calcium channel subtypes and highlight the complexity of using toxin-based tools for neuronal channel classification.

8670 records 17/578 page Previous Next First page 上5页 1617181920 下5页 Last page